New pill 申し込む／申し出s 肝炎 C 'cure'
A new pill 治療 that is said to 申し込む／申し出 a "cure" for the chronic 肝臓 病気 肝炎 C has been 開始する，打ち上げるd in the UK.
The 麻薬 daclatasvir can rid 90% or more 患者s of the 感染 in 12 weeks when 連合させるd with other スパイ／執行官s.
Used with another pill, sofosbuvir, it has produced 臨床の cure 率s of 89% and 98% in 患者s with different viral 緊張するs.
肝炎 C is 一般的に spread by 株ing needles and can hide for years without producing symptoms
基準 治療 for 肝炎 C 伴う／関わるs 注射s of the 免疫の system stimulator インターフェロン and can have serious 味方する 影響s. It typically 産する／生じるs cure 率s of 60% to 80%.
The 開始する，打ち上げる of daclatasvir makes a daily pill-only 治療 for the 病気 利用できる that b （犯罪の）一味s eradication of 肝炎 C a step closer.
Charles 血の塊／突き刺す, 長，指導者 (n)役員／(a)執行力のある of the 肝炎 C 信用, said: "We are delighted by today's 告示. Each new 治療 for 肝炎 C takes us closer to making the 排除／予選 of 肝炎 C a 現実主義の 可能性, by 改善するing both cure 率s and tolerability.
"With only 3% of people with 肝炎 C in England 接近ing 治療 each year, it is 決定的な 患者s are able to 接近 new 治療s as 早期に as possible so they have the 適切な時期 to get cured of this 癌-原因（となる）ing ウイルス."
肝炎 C, a 血-borne ウイルス 一般的に spread by 麻薬 takers 株ing needles, can hide for years without producing symptoms before 主要な to 潜在的に 致命的な 肝臓 損失 or 癌.
Deaths from the 感染 have almost quadrupled in the UK since 1996. Each year, more than 200,000 people are 感染させるd, but up to a half go undiagnosed.
裁判，公判 results showing the 有効性 of the pill 治療 were あられ／賞賛するd as a "turning point" by 専門家s when they 現れるd in April.
Dr Kosh Agarwal, from the 学校／設ける of 肝臓 熟考する／考慮するs at King's College London, who took part in the 研究, said: "Over the last １０年間 we have seen an alarming rise in the number of deaths and hospital visits 原因（となる）d by people with 肝炎 C.
" The 開始する，打ち上げる of this 治療 is welcome news as it 代表するs an important new 選択 for 患者s with chronic 肝炎 C that can 申し込む／申し出 high cure 率s for some 患者s, and be taken as a pill. Another 重要な point is that this 治療 除去するs the need to use インターフェロン, which is a 広範囲にわたって used 薬／医学 that often makes 患者s feel 極端に unwell."
When daclatasvir is 連合させるd with インターフェロン-alpha and the pill 麻薬 ribavirin, it can cure 100% of 患者s with the いっそう少なく ありふれた genotype 4 緊張する of the ウイルス.
Johanna Mercier, general 経営者／支配人 of the 製薬の company Bristol-Myers Squibb in the UK and Ireland, which makes the 麻薬, said: "We are committed to 改善するing the 質 of life of 患者s living with 肝炎 C and 覆うing the way to cure this chronic and 破滅的な 条件.
"熟考する／考慮する results have 最高潮の場面d that daclatasvir has the 可能性のある to 申し込む／申し出 high cure 率s, 顕著に 申し込む／申し出ing some of its most successful results in genotypes 1 and 3, which account for 90% of all 肝炎 C 事例／患者s in the UK."
In January daclatasvir was brought 今後 for 優先 review by the European 薬／医学s 機関 (EMA) in 承認 of the unmet 治療 need.
The 麻薬 belongs new to a new family of 製薬のs called NS5A inhibitors which 的 a 明確な／細部 protein in the 肝炎 C ウイルス.
